日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial

在表达 AR-V7 的转移性去势抵抗性前列腺癌中,纳武利尤单抗联合伊匹木单抗(加或不加恩扎卢胺)的疗效:一项 II 期非随机临床试验

Shenderov, Eugene; Boudadi, Karim; Fu, Wei; Wang, Hao; Sullivan, Rana; Jordan, Alice; Dowling, Donna; Harb, Rana; Schonhoft, Joseph; Jendrisak, Adam; Carducci, Michael A; Eisenberger, Mario A; Eshleman, James R; Luo, Jun; Drake, Charles G; Pardoll, Drew M; Antonarakis, Emmanuel S

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

伊匹木单抗联合纳武利尤单抗治疗AR-V7表达转移性前列腺癌中的DNA修复缺陷

Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo; Fu, Wei; Luber, Brandon; Wang, Hao; Niknafs, Noushin; White, James R; Silberstein, John L; Sullivan, Rana; Dowling, Donna; Harb, Rana; Nirschl, Thomas R; Veeneman, Brendan A; Tomlins, Scott A; Wang, Yipeng; Jendrisak, Adam; Graf, Ryon P; Dittamore, Ryan; Carducci, Michael A; Eisenberger, Mario A; Haffner, Michael C; Meeker, Alan K; Eshleman, James R; Luo, Jun; Velculescu, Victor E; Drake, Charles G; Antonarakis, Emmanuel S

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.

一项针对生化复发性前列腺癌男性患者的麝香葡萄皮提取物的 I 期研究:安全性、耐受性和剂量确定

Paller Channing J, Rudek Michelle A, Zhou Xian C, Wagner William D, Hudson Tamaro S, Anders Nicole, Hammers Hans J, Dowling Donna, King Serina, Antonarakis Emmanuel S, Drake Charles G, Eisenberger Mario A, Denmeade Samuel R, Rosner Gary L, Carducci Michael A